Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siMIAT
- Development stage
- Preclinical
- Lead developer
- University Hospital Bonn
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
siMIAT is a small interfering RNA (siRNA) designed to target and silence the long non-coding RNA (lncRNA) myocardial infarction-associated transcript (MIAT). MIAT is a key regulator implicated in chronic inflammation, progressive calcification, fibrosis, and endothelial dysfunction in cardiovascular pathologies such as aortic valve stenosis (AVS) and myocardial ischemia/reperfusion (MI/R) injury. By silencing MIAT, siMIAT attenuates endothelial-to-mesenchymal transition (EndMT), suppresses osteogenic drivers (such as BMP2 and RUNX2), and reduces calcification and inflammatory signaling. It is primarily utilized as a research reagent in preclinical and in vitro studies to investigate the therapeutic potential of targeting lncRNA pathways in cardiovascular and oncological diseases.
- Other names
- si-MIATsiRNA targeting MIATsmall interfering RNA targeting myocardial infarction-associated transcript
Beyond the preview
Go deeper on siMIAT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siMIAT.